Request for Nominations of Individuals and Consumer Organizations for the Digital Health Advisory Committee, 70674-70675 [2023-22567]
Download as PDF
70674
Federal Register / Vol. 88, No. 196 / Thursday, October 12, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
MEKINIST (trametinib dimethyl
sulfoxide) tablets, 1 mg, is currently
listed in the ‘‘Discontinued Drug
Product List’’ section of the Orange
Book. Apotex Inc., submitted a citizen
petition dated May 4, 2023 (Docket No.
FDA–2023–P–1795), under 21 CFR
10.30, requesting that the Agency
determine whether MEKINIST
(trametinib dimethyl sulfoxide) tablets,
1 mg, was withdrawn from sale for
reasons of safety or effectiveness.
After considering the citizen petition
and reviewing Agency records and
based on the information we have at this
time, FDA has determined under
§ 314.161 that MEKINIST (trametinib
dimethyl sulfoxide) tablets, 1 mg, was
not withdrawn for reasons of safety or
effectiveness. The petitioner has
identified no data or other information
suggesting that MEKINIST (trametinib
dimethyl sulfoxide) tablets, 1 mg, was
withdrawn for reasons of safety or
effectiveness. We have carefully
reviewed our files for records
concerning the withdrawal of
MEKINIST (trametinib dimethyl
sulfoxide) tablets, 1 mg, from sale. We
have also independently evaluated
relevant literature and data for possible
postmarketing adverse events. We have
found no information that would
indicate that this drug product was
withdrawn from sale for reasons of
safety or effectiveness.
Accordingly, the Agency will
continue to list MEKINIST (trametinib
dimethyl sulfoxide) tablets, 1 mg, in the
‘‘Discontinued Drug Product List’’
section of the Orange Book. The
‘‘Discontinued Drug Product List’’
delineates, among other items, drug
products that have been discontinued
from marketing for reasons other than
safety or effectiveness. ANDAs that refer
to MEKINIST (trametinib dimethyl
sulfoxide) tablets, 1 mg, may be
approved by the Agency as long as they
meet all other legal and regulatory
requirements for the approval of
ANDAs. If FDA determines that labeling
for this drug product should be revised
to meet current standards, the Agency
will advise ANDA applicants to submit
such labeling.
Dated: October 5, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–22464 Filed 10–11–23; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
17:34 Oct 11, 2023
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–0008]
Request for Nominations of Individuals
and Consumer Organizations for the
Digital Health Advisory Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
requesting nominations for a voting
consumer representative to serve on the
Digital Health Advisory Committee.
FDA is also requesting that any
consumer organizations interested in
participating in the selection of a voting
consumer representative to serve on the
Digital Health Advisory Committee
notify FDA in writing. Nominees
recommended to serve as a voting
consumer representative may either be
self-nominated or may be nominated by
a consumer organization. Nominations
will be accepted for the current vacancy
effective with this notice. FDA seeks to
include the views of members of all
gender groups, members of all racial and
ethnic groups, and individuals with and
without disabilities on its advisory
committees and, therefore encourages
nominations of appropriately qualified
candidates from these groups.
DATES: Any consumer organization
interested in participating in the
selection of an appropriate voting
member to represent consumer interests
on the Digital Health Advisory
Committee may send a letter or email
stating that interest to FDA (see
ADDRESSES) by November 27, 2023 for
vacancy listed in this notice.
Concurrently, nomination materials for
prospective candidates should be sent to
FDA (see ADDRESSES) by November 27,
2023. Nominations will be accepted for
current vacancy.
ADDRESSES: All statements of interest
from consumer organizations interested
in participating in the selection process
should be submitted electronically to
ACOMSSubmissions@fda.hhs.gov or by
mail to Advisory Committee and
Management Staff, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5122, Silver Spring,
MD 20993–0002.
Consumer representative nominations
should be submitted electronically by
logging into the FDA Advisory
Committee Membership Nomination
Portal: https://www.accessdata.fda.gov/
scripts/FACTRSPortal/FACTRS/
SUMMARY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
index.cfm or by mail to Advisory
Committee Oversight and Management
Staff, 10903 New Hampshire Ave., Bldg.
32, Rm. 5122, Silver Spring, MD 20993–
0002. Additional information about
becoming a member of an FDA advisory
committee can also be obtained by
visiting FDA’s website at https://
www.fda.gov/AdvisoryCommittees/
default.htm.
FOR FURTHER INFORMATION CONTACT:
For questions relating to participation
in the selection process: Kimberly
Hamilton, Advisory Committee
Oversight and Management Staff, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 5122,
Silver Spring, MD 20993–0002, 301–
796–8220, Kimberly.Hamilton@
fda.hhs.gov.
For questions relating to the Digital
Health Advisory Committee: James
Swink, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5211, Silver Spring,
MD 20993–0002, 301 796–6313,
James.Swink@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is
requesting nominations for a voting
consumer representative on the Digital
Health Advisory Committee. Elsewhere
in this Federal Register, FDA is
publishing separate documents
regarding:
1. Digital Health Advisory Committee;
Notice of Establishment
2. Request for Nominations for Voting
Members on a Public Advisory
Committee: Digital Health Advisory
Committee
3. Request for Nominations of
Individuals and Industry
Organizations for the Digital Health
Advisory Committee
I. Function and General Description of
the Committee Duties
Digital Health Advisory Committee
The Committee provides advice on
complex scientific and technical issues
related to Digital Health Technologies
(DHTs). This also may include advice
on the regulation of DHTs, and/or their
use, including use of DHTs in clinical
trials or postmarket studies subject to
FDA regulation. Topics relating to
DHTs, such as artificial intelligence/
machine learning, augmented reality,
virtual reality, digital therapeutics,
wearables, remote patient monitoring,
and software, may be considered by the
Committee. The Committee advises the
Commissioner on issues related to
DHTs, including, for example, realworld data, real-world evidence,
patient-generated health data,
E:\FR\FM\12OCN1.SGM
12OCN1
Federal Register / Vol. 88, No. 196 / Thursday, October 12, 2023 / Notices
interoperability, personalized medicine/
genetics, decentralized clinical trials,
use of DHTs in clinical trials for medical
products, cybersecurity, DHT user
experience, and Agency policies and
regulations regarding these
technologies. The Committee provides
relevant expertise and perspective to
improve Agency understanding of the
benefits, risks, and clinical outcomes
associated with use of DHTs.
ddrumheller on DSK120RN23PROD with NOTICES1
II. Criteria for Members
Persons nominated for membership as
a consumer representative on this
committee should meet the following
criteria: (1) demonstrate an affiliation
with and/or active participation in in
consumer or community-based
organizations, (2) be able to analyze
technical data, (3) understand research
design, (4) discuss benefits and risks,
and (5) evaluate the safety and efficacy
of products under review. The
consumer representative should be able
to represent the consumer perspective
on issues and actions before the
advisory committee; serve as a liaison
between the committee and interested
consumers, associations, coalitions, and
consumer organizations; and facilitate
dialogue with the advisory committees
on scientific issues that affect
consumers.
III. Selection Procedures
Selection of members representing
consumer interests is conducted
through procedures that include the use
of organizations representing the public
interest and public advocacy groups.
These organizations recommend
nominees for the Agency’s selection.
Representatives from the consumer
health branches of Federal, State, and
local governments also may participate
in the selection process. Any consumer
organization interested in participating
in the selection of an appropriate voting
member to represent consumer interests
should send a letter stating that interest
to FDA (see ADDRESSES) within 30 days
of publication of this document.
Within the subsequent 45 days, FDA
will compile a list of consumer
organizations that will participate in the
selection process and will forward to
each such organization a ballot listing at
least two qualified nominees selected by
the Agency based on the nominations
received, together with each nominee’s
current curriculum vitae or re´sume´.
Ballots are to be filled out and returned
to FDA within 30 days. The nominee
receiving the highest number of votes
ordinarily will be selected to serve as
the member representing consumer
interests for that particular advisory
committee.
VerDate Sep<11>2014
17:34 Oct 11, 2023
Jkt 262001
IV. Nomination Procedures
Any interested person or organization
may nominate one or more qualified
persons to represent consumer interests
on the Digital Health Advisory
Committee with the exception of the
following: individuals who are not U.S.
citizens or nationals cannot be
appointed as Advisory Committee
Members (42 U.S.C. 217(a)) in FDA.
Self-nominations are also accepted.
Nominations must include a current,
complete re´sume´ or curriculum vitae for
each nominee, including current
business and/or home address,
telephone number, and email address if
available; a signed copy of the
Acknowledgment and Consent form
available at the FDA Advisory
Nomination Portal (see ADDRESSES), and
a list of consumer or community-based
organizations for which the candidate
can demonstrate active participation.
Nominations should also specify the
advisory committee for which the
nominee is recommended. In addition,
nominations must also acknowledge
that the nominee is aware of the
nomination, unless self-nominated. FDA
will ask potential candidates to provide
detailed information concerning such
matters related to financial holdings,
employment, and research grants and/or
contracts to permit evaluation of
possible sources of conflicts of interest.
Members will be invited to serve for
terms up to 4 years.
FDA will review all nominations
received within the specified
timeframes and prepare a ballot
containing the names of qualified
nominees. Names not selected will
remain on a list of eligible nominees
and be reviewed periodically by FDA to
determine continued interest. After
selecting qualified nominees for the
ballot, FDA will provide those
consumer organizations that are
participating in the selection process
with the opportunity to vote on the
listed nominees. Only organizations
vote in the selection process. Persons
who nominate themselves to serve as
voting consumer representatives will
not participate in the selection process.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: October 6, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–22567 Filed 10–11–23; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
70675
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–0008]
Request for Nominations of Individuals
and Industry Organizations for the
Digital Health Advisory Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
requesting nominations for temporary
nonvoting industry representatives to be
included in a pool of individuals to
serve on the Digital Health Advisory
Committee. FDA is also requesting that
industry organizations interested in
participating in the selection of a pool
of nonvoting industry representatives to
serve as temporary nonvoting members
on the Digital Health Advisory
Committee (the Committee) in the
Center for Devices and Radiological
Health notify FDA in writing. Nominees
recommended to serve as a temporary
nonvoting industry representative may
either be self-nominated or nominated
by an industry organization. This
position may be filled by representatives
of different medical device areas based
on areas of expertise relevant to the
topics being considered by the
Committee. Nominations will be
accepted for current vacancies effective
with this notice. FDA seeks to include
the views of members of all gender
groups, members of all racial and ethnic
groups, and individuals with and
without disabilities on its advisory
committees and, therefore encourages
nominations of appropriately qualified
candidates from these groups.
DATES: Any industry organization
interested in participating in the
selection of an appropriate nonvoting
member to represent industry interest,
must send a letter stating that interest to
the FDA by November 13, 2023, (see
sections I and II of this document for
details). Concurrently, nomination
materials for prospective candidates
should be sent to FDA by November 13,
2023.
ADDRESSES: All statements of interest
from interested industry organizations
interested in participating in the
selection process of a pool of nonvoting
industry representatives should be sent
electronically to Margaret Ames (see FOR
FURTHER INFORMATION CONTACT). All
nominations for nonvoting industry
representatives may be submitted
electronically by accessing the FDA
SUMMARY:
E:\FR\FM\12OCN1.SGM
12OCN1
Agencies
[Federal Register Volume 88, Number 196 (Thursday, October 12, 2023)]
[Notices]
[Pages 70674-70675]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-22567]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-N-0008]
Request for Nominations of Individuals and Consumer Organizations
for the Digital Health Advisory Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is requesting
nominations for a voting consumer representative to serve on the
Digital Health Advisory Committee. FDA is also requesting that any
consumer organizations interested in participating in the selection of
a voting consumer representative to serve on the Digital Health
Advisory Committee notify FDA in writing. Nominees recommended to serve
as a voting consumer representative may either be self-nominated or may
be nominated by a consumer organization. Nominations will be accepted
for the current vacancy effective with this notice. FDA seeks to
include the views of members of all gender groups, members of all
racial and ethnic groups, and individuals with and without disabilities
on its advisory committees and, therefore encourages nominations of
appropriately qualified candidates from these groups.
DATES: Any consumer organization interested in participating in the
selection of an appropriate voting member to represent consumer
interests on the Digital Health Advisory Committee may send a letter or
email stating that interest to FDA (see ADDRESSES) by November 27, 2023
for vacancy listed in this notice. Concurrently, nomination materials
for prospective candidates should be sent to FDA (see ADDRESSES) by
November 27, 2023. Nominations will be accepted for current vacancy.
ADDRESSES: All statements of interest from consumer organizations
interested in participating in the selection process should be
submitted electronically to [email protected] or by mail to
Advisory Committee and Management Staff, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 32, Rm. 5122, Silver Spring, MD 20993-
0002.
Consumer representative nominations should be submitted
electronically by logging into the FDA Advisory Committee Membership
Nomination Portal: https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm or by mail to Advisory Committee Oversight and
Management Staff, 10903 New Hampshire Ave., Bldg. 32, Rm. 5122, Silver
Spring, MD 20993-0002. Additional information about becoming a member
of an FDA advisory committee can also be obtained by visiting FDA's
website at https://www.fda.gov/AdvisoryCommittees/default.htm.
FOR FURTHER INFORMATION CONTACT:
For questions relating to participation in the selection process:
Kimberly Hamilton, Advisory Committee Oversight and Management Staff,
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm.
5122, Silver Spring, MD 20993-0002, 301-796-8220,
[email protected].
For questions relating to the Digital Health Advisory Committee:
James Swink, Center for Devices and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5211, Silver
Spring, MD 20993-0002, 301 796-6313, [email protected].
SUPPLEMENTARY INFORMATION: FDA is requesting nominations for a voting
consumer representative on the Digital Health Advisory Committee.
Elsewhere in this Federal Register, FDA is publishing separate
documents regarding:
1. Digital Health Advisory Committee; Notice of Establishment
2. Request for Nominations for Voting Members on a Public Advisory
Committee: Digital Health Advisory Committee
3. Request for Nominations of Individuals and Industry Organizations
for the Digital Health Advisory Committee
I. Function and General Description of the Committee Duties
Digital Health Advisory Committee
The Committee provides advice on complex scientific and technical
issues related to Digital Health Technologies (DHTs). This also may
include advice on the regulation of DHTs, and/or their use, including
use of DHTs in clinical trials or postmarket studies subject to FDA
regulation. Topics relating to DHTs, such as artificial intelligence/
machine learning, augmented reality, virtual reality, digital
therapeutics, wearables, remote patient monitoring, and software, may
be considered by the Committee. The Committee advises the Commissioner
on issues related to DHTs, including, for example, real-world data,
real-world evidence, patient-generated health data,
[[Page 70675]]
interoperability, personalized medicine/genetics, decentralized
clinical trials, use of DHTs in clinical trials for medical products,
cybersecurity, DHT user experience, and Agency policies and regulations
regarding these technologies. The Committee provides relevant expertise
and perspective to improve Agency understanding of the benefits, risks,
and clinical outcomes associated with use of DHTs.
II. Criteria for Members
Persons nominated for membership as a consumer representative on
this committee should meet the following criteria: (1) demonstrate an
affiliation with and/or active participation in in consumer or
community-based organizations, (2) be able to analyze technical data,
(3) understand research design, (4) discuss benefits and risks, and (5)
evaluate the safety and efficacy of products under review. The consumer
representative should be able to represent the consumer perspective on
issues and actions before the advisory committee; serve as a liaison
between the committee and interested consumers, associations,
coalitions, and consumer organizations; and facilitate dialogue with
the advisory committees on scientific issues that affect consumers.
III. Selection Procedures
Selection of members representing consumer interests is conducted
through procedures that include the use of organizations representing
the public interest and public advocacy groups. These organizations
recommend nominees for the Agency's selection. Representatives from the
consumer health branches of Federal, State, and local governments also
may participate in the selection process. Any consumer organization
interested in participating in the selection of an appropriate voting
member to represent consumer interests should send a letter stating
that interest to FDA (see ADDRESSES) within 30 days of publication of
this document.
Within the subsequent 45 days, FDA will compile a list of consumer
organizations that will participate in the selection process and will
forward to each such organization a ballot listing at least two
qualified nominees selected by the Agency based on the nominations
received, together with each nominee's current curriculum vitae or
r[eacute]sum[eacute]. Ballots are to be filled out and returned to FDA
within 30 days. The nominee receiving the highest number of votes
ordinarily will be selected to serve as the member representing
consumer interests for that particular advisory committee.
IV. Nomination Procedures
Any interested person or organization may nominate one or more
qualified persons to represent consumer interests on the Digital Health
Advisory Committee with the exception of the following: individuals who
are not U.S. citizens or nationals cannot be appointed as Advisory
Committee Members (42 U.S.C. 217(a)) in FDA. Self-nominations are also
accepted. Nominations must include a current, complete
r[eacute]sum[eacute] or curriculum vitae for each nominee, including
current business and/or home address, telephone number, and email
address if available; a signed copy of the Acknowledgment and Consent
form available at the FDA Advisory Nomination Portal (see ADDRESSES),
and a list of consumer or community-based organizations for which the
candidate can demonstrate active participation.
Nominations should also specify the advisory committee for which
the nominee is recommended. In addition, nominations must also
acknowledge that the nominee is aware of the nomination, unless self-
nominated. FDA will ask potential candidates to provide detailed
information concerning such matters related to financial holdings,
employment, and research grants and/or contracts to permit evaluation
of possible sources of conflicts of interest. Members will be invited
to serve for terms up to 4 years.
FDA will review all nominations received within the specified
timeframes and prepare a ballot containing the names of qualified
nominees. Names not selected will remain on a list of eligible nominees
and be reviewed periodically by FDA to determine continued interest.
After selecting qualified nominees for the ballot, FDA will provide
those consumer organizations that are participating in the selection
process with the opportunity to vote on the listed nominees. Only
organizations vote in the selection process. Persons who nominate
themselves to serve as voting consumer representatives will not
participate in the selection process.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: October 6, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-22567 Filed 10-11-23; 8:45 am]
BILLING CODE 4164-01-P